查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1859716

藥物基因體學技術市場預測至2032年：按產品/服務、技術、應用、最終用戶和地區分類的全球分析

Pharmacogenomics Technology Market Forecasts to 2032 - Global Analysis By Product & Service (Instruments, Reagents & Kits, Software, Services and Consumables), Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球藥物基因體學技術市場預計到 2025 年將達到 84 億美元，到 2032 年將達到 164 億美元，預測期內複合年成長率為 10.1%。

藥物基因體學技術是研究和應用個別基因組成如何影響藥物反應的學科。透過分析影響藥物代謝、療效和安全性的基因變異，該技術能夠制定針對每位患者的個人化醫療策略。它整合了基因組學、生物資訊學和分子生物學，以預測藥物反應、最大限度地減少副作用並最佳化治療效果。藥物基因體學技術廣泛應用於藥物研發、臨床試驗和患者照護，以指南劑量調整和藥物選擇。其應用旨在提高治療效果、降低醫療成本並促進精準醫療的發展。

根據世界衛生組織 (WHO) 2023 年 5 月發布的報告，心血管疾病、糖尿病、癌症和呼吸系統疾病等慢性疾病預計將佔全球整體死亡人數的 86%，比 2019 年增加了 90%。

對個人化醫療的需求日益成長

醫生和研究人員正在利用基因資訊為每位患者量身定做藥物劑量和治療方案。該平台支援腫瘤學、心臟病學、精神病學和感染疾病等領域的基因型鑒定、定序和生物標記分析。與電子健康記錄和臨床決策支援工具的整合提高了準確性和工作流程效率。醫院網路、學術中心和生物製藥研發管線對預測性和病患特異性診斷的需求日益成長。這些趨勢正在推動該平台在個人化醫療生態系統中的部署。

臨床應用有限

儘管研究結果有力地檢驗了基因檢測的有效性，但許多醫療系統缺乏將基因檢測整合到常規診療中的基礎設施、訓練和獎勵。醫生在解讀檢測結果並將其與處方指南和臨床方案相協調方面面臨許多挑戰。支付方不願為缺乏明確成本效益證據或長期療效數據的檢測項目買單。監管政策的模糊性和零散的實施進一步延緩了臨床整合和相關人員的協調。這些限制因素阻礙了基因檢測平台的成熟和在醫療系統中的主流推廣應用。

活性化研發活動

政府學術機構和生物製藥公司正在投資進行大規模人群藥物反應建模和生物標記發現研究。相關平台支援將高通量定序與機器學習和多體學相結合，以提高預測準確性和治療相關性。臨床試驗、藥物開發和轉化研究對可擴展且可互通的工具的需求日益成長。診斷公司和製藥公司之間的夥伴關係正在加速共同開發，並促進與監管機構的合作。這些趨勢正在推動以研究主導、以創新為中心的藥物基因體學平台的整體發展。

不同族群代表性不足

大多數資料集和演算法都偏向歐洲裔人群，這限制了其普適性和治療效果。少數族群群體在參與基因研究和檢測計畫以及對其信任方面面臨許多障礙。缺乏全面的數據阻礙了全球人群中生物標記的發現、劑量最佳化和不利事件預測。監管機構和倡導團體呼籲制定多元化要求和倫理框架來彌補這些差距。這些限制持續限制藥物基因組學生態系統中平台的表現和公平應用。

新冠疫情的影響：

疫情擾亂了臨床試驗診斷和藥物基因體學技術的供應鏈。封鎖和資源重新分配延緩了樣本採集、檢測方法開發和法規核准。然而，隨著研究人員探索藥物反應、疫苗效力和疾病嚴重程度的遺傳因素，人們對個人化醫療的興趣日益濃厚。對遠距檢測、數位醫療和人群藥物基因體學的投資加速了平台創新和普及。消費者和臨床群體對基因檢測和精準醫療的認知度不斷提高。這些變化強化了對藥物基因組學基礎設施和轉化研究的長期投資。

預計試劑和試劑盒細分市場在預測期內將成為最大的細分市場。

預計在預測期內，試劑和試劑盒領域將佔據最大的市場佔有率，因為它們在整個藥物基因體學工作流程中發揮基因型鑒定、測序和生物標記分析的基礎性作用。平台為臨床和研究環境中的DNA提取、PCR擴增和變異檢測提供標準化且可擴展的解決方案。與自動化設備和生物資訊流程的整合提高了通量準確性和可重複性。醫院實驗室、學術中心和生物製藥臨床試驗對經過驗證的、符合監管標準的試劑的需求正在成長。供應商提供針對特定疾病的伴隨診斷試劑盒和針對特定治療領域的模組化試劑盒。

預計在預測期內，生物製藥公司板塊的複合年成長率將最高。

預計在預測期內，生物製藥公司將實現最高成長率，因為它們將藥物基因體學融入藥物發現的臨床試驗和監管申報流程中。相關平台支援臨床前和臨床階段的患者分層、劑量最佳化和不利事件預測。與真實數據人工智慧引擎和監管框架的整合，能夠最佳化試驗設計和治療標靶性。免疫腫瘤學和中樞神經系統藥物研發管線正在推動以生物標記為導向的精準開發的需求。這些因素共同促進了生物製藥主導藥物基因組學技術的廣泛應用。

佔比最大的地區：

由於北美擁有先進的研究基礎設施、積極的監管參與以及藥物基因組學技術的臨床應用，預計在預測期內，北美將佔據最大的市場佔有率。企業和學術機構正在腫瘤學、精神病學和感染疾病計畫中部署定序和決策支援工具的平台。對人群基因組學報銷框架和數位健康整合的投資有助於擴充性和可及性。主要診斷機構、生物製藥公司和監管機構的存在正在推動創新和標準化。各公司正根據FDA的指導、NIH的資助和支付方的參與情況調整其平台策略。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於醫療現代化、基因組醫學和生物製藥領域的投資在整個區域經濟中的整合。中國、印度、日本和韓國等國家正在公共衛生、學術研究和臨床新興企業擴展藥物基因體學學平台。政府支持的舉措正在推動個人化醫療領域的基礎建設、新創企業孵化和國際合作。本地企業正在提供經濟高效且在地化的解決方案，以滿足疾病特徵和合規性需求。腫瘤學、感染疾病和慢性病領域對可擴展且符合當地文化的藥物基因體學平台的需求日益成長。這些趨勢正在推動亞太地區藥物基因組學創新和應用的成長。

免費客製化服務：

訂閱本報告的用戶可免費獲得以下自訂選項之一：

  • 公司簡介
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要企業進行SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家進行市場估算、預測和複合年成長率分析（註：基於可行性檢查）
  • 競爭基準化分析
    • 基於產品系列、地域覆蓋和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 研究途徑
  • 研究材料
    • 原始研究資料
    • 二手研究資料
    • 先決條件

第3章 市場趨勢分析

  • 促進要素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 技術分析
  • 應用分析
  • 終端用戶分析
  • 新興市場
  • 新冠疫情的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球藥物基因體學技術市場（按產品和服務分類）

  • 裝置
  • 試劑和試劑盒
  • 軟體
  • 服務
  • 消耗品

6. 全球藥物基因體學技術市場（依技術分類）

  • 聚合酵素鏈鎖反應（PCR）
  • DNA序列分析
  • 微陣列
  • 質譜分析
  • 電泳
  • 原位雜合技術
  • 生物資訊學和人工智慧平台
  • 樣品製備與萃取技術
  • 其他技術

7. 全球藥物基因體學技術市場（按應用分類）

  • 腫瘤學
  • 感染疾病
  • 心血管疾病
  • 神經系統疾病
  • 精神病學
  • 疼痛管理
  • 其他用途

8. 全球藥物基因體學技術市場（依最終用戶分類）

  • 醫院和診所
  • 學術和研究機構
  • 診斷檢查室
  • 生物製藥公司
  • 其他最終用戶

9. 全球藥物基因體學技術市場（按地區分類）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 亞太其他地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美洲
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第10章：重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與併購
  • 新產品上市
  • 業務拓展
  • 其他關鍵策略

第11章 企業概況

  • F. Hoffmann-La Roche Ltd.
  • Thermo Fisher Scientific Inc.
  • Illumina Inc.
  • QIAGEN NV
  • Agilent Technologies Inc.
  • Bio-Rad Laboratories Inc.
  • Myriad Genetics Inc.
  • 23andMe Holding Co.
  • GenScript Biotech Corporation
  • Eurofins Scientific SE
  • Beckman Coulter Inc.
  • Becton, Dickinson and Company
  • PerkinElmer Inc.
  • SomaLogic Inc.
  • Color Health Inc.
Product Code: SMRC31940

According to Stratistics MRC, the Global Pharmacogenomics Technology Market is accounted for $8.4 billion in 2025 and is expected to reach $16.4 billion by 2032 growing at a CAGR of 10.1% during the forecast period. Pharmacogenomics technology is the study and application of how an individual's genetic makeup influences their response to drugs. By analyzing variations in genes that affect drug metabolism, efficacy, and safety, this technology enables the development of personalized medicine strategies tailored to each patient. It integrates genomics, bioinformatics, and molecular biology to predict drug response, minimize adverse effects, and optimize therapeutic outcomes. Pharmacogenomics technology is widely used in drug discovery, clinical trials, and patient care, guiding dosage adjustments and drug selection. Its implementation aims to enhance treatment effectiveness, reduce healthcare costs, and advance precision medicine.

According to a World Health Organization (WHO) report published in May 2023, chronic diseases such as cardiovascular diseases, diabetes, cancer, and respiratory illnesses are expected to cause 86% of all deaths globally, representing a 90% increase since 2019.

Market Dynamics:

Driver:

Rising demand for personalized medicine

Physicians and researchers are leveraging genetic insights to tailor drug selection dosage and treatment plans for individual patients. Platforms support genotyping sequencing and biomarker analysis across oncology cardiology psychiatry and infectious diseases. Integration with electronic health records and clinical decision support tools enhances precision and workflow efficiency. Demand for predictive and patient-specific diagnostics is rising across hospital networks academic centers and biopharma pipelines. These dynamics are propelling platform deployment across personalized medicine ecosystems.

Restraint:

Limited clinical implementation

Despite strong research validation many healthcare systems lack infrastructure training and incentives to integrate genetic testing into routine care. Physicians face challenges in interpreting results and aligning them with formulary guidelines and clinical protocols. Payers remain hesitant to cover tests without clear cost-benefit evidence or long-term outcomes data. Regulatory ambiguity and fragmented adoption further delay clinical integration and stakeholder alignment. These constraints continue to hinder platform maturity and mainstream deployment across healthcare systems.

Opportunity:

Increased research and development activities

Government's academic institutions and biopharma firms are investing in population-scale studies drug response modeling and biomarker discovery. Platforms support high-throughput sequencing machine learning and multi-omics integration to enhance predictive accuracy and therapeutic relevance. Demand for scalable and interoperable tools is rising across clinical trials drug development and translational research. Partnerships between diagnostics firms and pharmaceutical companies are accelerating co-development and regulatory alignment. These trends are fostering growth across research-driven and innovation-centric pharmacogenomics platforms.

Threat:

Underrepresentation of diverse populations

Most datasets and algorithms are biased toward populations of European ancestry limiting generalizability and therapeutic efficacy. Minority groups face barriers in access participation and trust across genetic research and testing programs. Lack of inclusive data hampers biomarker discovery dosage optimization and adverse event prediction across global populations. Regulatory bodies and advocacy groups are calling for diversity mandates and ethical frameworks to address these gaps. These limitations continue to constrain platform performance and equitable adoption across pharmacogenomics ecosystems.

Covid-19 Impact:

The pandemic disrupted clinical trials diagnostics and supply chains across pharmacogenomics technologies. Lockdowns and resource reallocation delayed sample collection assay development and regulatory review. However interest in personalized medicine surged as researchers explored genetic factors in drug response vaccine efficacy and disease severity. Investment in remote testing digital health and population genomics accelerated platform innovation and accessibility. Public awareness of genetic testing and precision medicine increased across consumer and clinical segments. These shifts are reinforcing long-term investment in pharmacogenomics infrastructure and translational research.

The reagents & kits segment is expected to be the largest during the forecast period

The reagents & kits segment is expected to account for the largest market share during the forecast period due to their foundational role in enabling genotyping sequencing and biomarker analysis across pharmacogenomics workflows. Platforms offer standardized and scalable solutions for DNA extraction PCR amplification and variant detection across clinical and research settings. Integration with automation instruments and bioinformatics pipelines enhances throughput accuracy and reproducibility. Demand for validated and regulatory-grade reagents is rising across hospital labs academic centers and biopharma trials. Vendors offer disease-specific panels companion diagnostics and modular kits tailored to therapeutic areas.

The biopharmaceutical companies segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the biopharmaceutical companies segment is predicted to witness the highest growth rate as firms integrate pharmacogenomics into drug discovery clinical trials and regulatory submissions. Platforms support patient stratification dose optimization and adverse event prediction across preclinical and clinical phases. Integration with real-world data AI engines and regulatory frameworks enhances trial design and therapeutic targeting. Demand for precision-driven and biomarker-aligned development is rising across oncology immunology and CNS pipelines. These dynamics are accelerating growth across biopharma-led pharmacogenomics technology adoption.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share due to its advanced research infrastructure regulatory engagement and clinical adoption across pharmacogenomics technologies. Enterprises and academic institutions deploy platforms across oncology psychiatry and infectious disease programs with integrated sequencing and decision support tools. Investment in population genomics reimbursement frameworks and digital health integration supports scalability and accessibility. Presence of leading diagnostics firms biopharma companies and regulatory bodies drives innovation and standardization. Firms align platform strategies with FDA guidance NIH funding and payer engagement.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR as healthcare modernization genomic medicine and biopharma investment converge across regional economies. Countries like China India Japan and South Korea scale pharmacogenomics platforms across public health academic research and clinical diagnostics. Government-backed initiatives support infrastructure development startup incubation and international collaboration across personalized medicine. Local firms offer cost-effective and regionally adapted solutions tailored to disease profiles and compliance needs. Demand for scalable and culturally aligned pharmacogenomics platforms is rising across oncology infectious diseases and chronic conditions. These trends are accelerating regional growth across pharmacogenomics innovation and deployment.

Key players in the market

Some of the key players in Pharmacogenomics Technology Market include F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Illumina Inc., QIAGEN N.V., Agilent Technologies Inc., Bio-Rad Laboratories Inc., Myriad Genetics Inc., 23andMe Holding Co., GenScript Biotech Corporation, Eurofins Scientific SE, Beckman Coulter Inc., Becton, Dickinson and Company, PerkinElmer Inc., SomaLogic Inc. and Color Health Inc.

Key Developments:

In October 2025, Roche unveiled major advances in its Sequencing by Expansion (SBX) technology at the ASHG Conference. The platform enabled bulk RNA sequencing, methylation mapping, and spatial multiomics, unlocking pharmacogenomic insights previously inaccessible with short-read platforms. Roche's SBX system was used by Broad Clinical Labs to set a GUINNESS WORLD RECORD(TM) for fastest DNA sequencing in under four hours.

In February 2025, Illumina unveiled its multiomics roadmap, expanding into spatial transcriptomics, single-cell analysis, CRISPR screening, and methylation profiling. These technologies were built on Illumina's core sequencing platforms and supported pharmacogenomic applications in drug response prediction and biomarker discovery. The launch positioned Illumina as a leader in integrated omics for precision medicine.

Product & Services Covered:

  • Instruments
  • Reagents & Kits
  • Software
  • Services
  • Consumables

Technologies Covered:

  • Polymerase Chain Reaction (PCR)
  • DNA Sequencing
  • Microarray
  • Mass Spectrometry
  • Electrophoresis
  • In-Situ Hybridization
  • Bioinformatics & AI Platforms
  • Sample Preparation & Extraction Technologies
  • Other Technologies

Applications Covered:

  • Oncology
  • Infectious Diseases
  • Cardiovascular Diseases
  • Neurological Disorders
  • Psychiatry
  • Pain Management
  • Other Applications

End Users Covered:

  • Hospitals & Clinics
  • Academic & Research Institutes
  • Diagnostic Laboratories
  • Biopharmaceutical Companies
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Technology Analysis
  • 3.8 Application Analysis
  • 3.9 End User Analysis
  • 3.10 Emerging Markets
  • 3.11 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Pharmacogenomics Technology Market, By Product & Service

  • 5.1 Introduction
  • 5.2 Instruments
  • 5.3 Reagents & Kits
  • 5.4 Software
  • 5.5 Services
  • 5.6 Consumables

6 Global Pharmacogenomics Technology Market, By Technology

  • 6.1 Introduction
  • 6.2 Polymerase Chain Reaction (PCR)
  • 6.3 DNA Sequencing
  • 6.4 Microarray
  • 6.5 Mass Spectrometry
  • 6.6 Electrophoresis
  • 6.7 In-Situ Hybridization
  • 6.8 Bioinformatics & AI Platforms
  • 6.9 Sample Preparation & Extraction Technologies
  • 6.10 Other Technologies

7 Global Pharmacogenomics Technology Market, By Application

  • 7.1 Introduction
  • 7.2 Oncology
  • 7.3 Infectious Diseases
  • 7.4 Cardiovascular Diseases
  • 7.5 Neurological Disorders
  • 7.6 Psychiatry
  • 7.7 Pain Management
  • 7.8 Other Applications

8 Global Pharmacogenomics Technology Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals & Clinics
  • 8.3 Academic & Research Institutes
  • 8.4 Diagnostic Laboratories
  • 8.5 Biopharmaceutical Companies
  • 8.6 Other End Users

9 Global Pharmacogenomics Technology Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 F. Hoffmann-La Roche Ltd.
  • 11.2 Thermo Fisher Scientific Inc.
  • 11.3 Illumina Inc.
  • 11.4 QIAGEN N.V.
  • 11.5 Agilent Technologies Inc.
  • 11.6 Bio-Rad Laboratories Inc.
  • 11.7 Myriad Genetics Inc.
  • 11.8 23andMe Holding Co.
  • 11.9 GenScript Biotech Corporation
  • 11.10 Eurofins Scientific SE
  • 11.11 Beckman Coulter Inc.
  • 11.12 Becton, Dickinson and Company
  • 11.13 PerkinElmer Inc.
  • 11.14 SomaLogic Inc.
  • 11.15 Color Health Inc.

List of Tables

  • Table 1 Global Pharmacogenomics Technology Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Pharmacogenomics Technology Market Outlook, By Product & Service (2024-2032) ($MN)
  • Table 3 Global Pharmacogenomics Technology Market Outlook, By Instruments (2024-2032) ($MN)
  • Table 4 Global Pharmacogenomics Technology Market Outlook, By Reagents & Kits (2024-2032) ($MN)
  • Table 5 Global Pharmacogenomics Technology Market Outlook, By Software (2024-2032) ($MN)
  • Table 6 Global Pharmacogenomics Technology Market Outlook, By Services (2024-2032) ($MN)
  • Table 7 Global Pharmacogenomics Technology Market Outlook, By Consumables (2024-2032) ($MN)
  • Table 8 Global Pharmacogenomics Technology Market Outlook, By Technology (2024-2032) ($MN)
  • Table 9 Global Pharmacogenomics Technology Market Outlook, By Polymerase Chain Reaction (PCR) (2024-2032) ($MN)
  • Table 10 Global Pharmacogenomics Technology Market Outlook, By DNA Sequencing (2024-2032) ($MN)
  • Table 11 Global Pharmacogenomics Technology Market Outlook, By Microarray (2024-2032) ($MN)
  • Table 12 Global Pharmacogenomics Technology Market Outlook, By Mass Spectrometry (2024-2032) ($MN)
  • Table 13 Global Pharmacogenomics Technology Market Outlook, By Electrophoresis (2024-2032) ($MN)
  • Table 14 Global Pharmacogenomics Technology Market Outlook, By In-Situ Hybridization (2024-2032) ($MN)
  • Table 15 Global Pharmacogenomics Technology Market Outlook, By Bioinformatics & AI Platforms (2024-2032) ($MN)
  • Table 16 Global Pharmacogenomics Technology Market Outlook, By Sample Preparation & Extraction Technologies (2024-2032) ($MN)
  • Table 17 Global Pharmacogenomics Technology Market Outlook, By Other Technologies (2024-2032) ($MN)
  • Table 18 Global Pharmacogenomics Technology Market Outlook, By Application (2024-2032) ($MN)
  • Table 19 Global Pharmacogenomics Technology Market Outlook, By Oncology (2024-2032) ($MN)
  • Table 20 Global Pharmacogenomics Technology Market Outlook, By Infectious Diseases (2024-2032) ($MN)
  • Table 21 Global Pharmacogenomics Technology Market Outlook, By Cardiovascular Diseases (2024-2032) ($MN)
  • Table 22 Global Pharmacogenomics Technology Market Outlook, By Neurological Disorders (2024-2032) ($MN)
  • Table 23 Global Pharmacogenomics Technology Market Outlook, By Psychiatry (2024-2032) ($MN)
  • Table 24 Global Pharmacogenomics Technology Market Outlook, By Pain Management (2024-2032) ($MN)
  • Table 25 Global Pharmacogenomics Technology Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 26 Global Pharmacogenomics Technology Market Outlook, By End User (2024-2032) ($MN)
  • Table 27 Global Pharmacogenomics Technology Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
  • Table 28 Global Pharmacogenomics Technology Market Outlook, By Academic & Research Institutes (2024-2032) ($MN)
  • Table 29 Global Pharmacogenomics Technology Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
  • Table 30 Global Pharmacogenomics Technology Market Outlook, By Biopharmaceutical Companies (2024-2032) ($MN)
  • Table 31 Global Pharmacogenomics Technology Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.